810429 MingMed Biotechnology Co., Ltd.
- 0.000
- 0.0000.00%
MingMed Biotechnology Co., Ltd. News
Since Ming Biotech submitted to the Hong Kong Stock Exchange, Gao Rong Capital is the largest external institutional investor, with a diversified product pipeline layout in four major areas
As an innovation-driven biopharmaceutical company, Ming Biotech is committed to the independent discovery and development of innovative drugs to address unmet clinical needs in many medical fields around the world.
IPO News | The potential of core products highlights the accumulation of new drug layouts! Yinming Biotech submits its list to the Hong Kong Stock Exchange
The Zhitong Finance App learned that on August 17, innovation-driven biopharmaceutical company Yiming Biotech submitted a Hong Kong stock listing application. Since its establishment in 2016, Yinming Biotech has been committed to independently discovering and developing novel potential first innovative drugs to address unmet clinical needs in many medical fields around the world. Yiming Biotech is one of the few pharmaceutical companies in China that has in-house independent research and development capabilities and uses scientific breakthroughs as the driving force to independently develop potential pioneering drugs of the same kind. With its strong R&D and operation capabilities, Ming Biotech has built a rich and diverse product pipeline, with 7 major drugs under development (6 clinical stages), involving
Yiming Biotech submitted a prospectus and plans to go public in Hong Kong for IPO
August 17, 2022, Guangzhou Yinming Biomedical Technology Co., Ltd. from Guangzhou, Guangdong MingMed Biotechnology Co., Ltd. , Ltd (“Yinming Biotech” for short) submitted a prospectus to the Hong Kong Stock Exchange and plans to be listed on the Hong Kong Main Board as an IPO.
As Ming Biotech sprinted to the Hong Kong Stock Exchange: the product pipeline covers four major fields, and many of the first innovative drugs have already entered the clinical stage
As Ming Biotech sprinted to the Hong Kong Stock Exchange: the product pipeline covers four major fields, and many of the first innovative drugs have already entered the clinical stage
No Data